Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis

Recruiting Observational Study
Dermatomyositis
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Observational
Participants needed
200 (estimated)
Sponsor
Central Hospital, Nancy, France · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Dermatomyositis (DM) are rare and heterogeneous systemic autoimmune diseases, characterized by the association of muscle inflammation, skin inflammation and vasculopathy. DM concern both adults and children. DM can be life-threatening (interstitial lung disease, infectious complications) and responsible of significant functional disability (muscle weakness). Age of onset appear to be an independen…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patient with dermatomyositis according to 2017 American College of Rheumatology (ACR)/ European Alliance of Associations for Rheumatology (EULAR) classification Exclusion Criteria: * Patient with cancer-associated dermatomyositis (within 3 years before or after diagnosis of …
Contacts

Paul Decker, MD

+33383157240

p.decker@chru-nancy.fr

CONTACT